Zaleplon
Sonata
Pyrazolopyrimidine Z-Drug (Non-BZD)Schedule IVGeneric availableTDM data
Zaleplon is a non-benzodiazepine hypnotic that binds selectively to the omega-1 receptor on the alpha-1 subunit of the GABA-A/chloride ion channel receptor complex. Subunit modulation of GABA-A receptors produces hyperpolarization and decreased neuronal excitability. Ultra-short acting with terminal half-life of approximately 1 hour, making it ideal for middle-of-the-night awakening without next-day residual effects. No active metabolites; all metabolites are pharmacologically inactive.
Compare Zaleplon →FDA-Approved Indications
- Short-term treatment of insomnia (sleep-onset)
Common Off-Label Uses
- Middle-of-night dosing for nighttime awakening (can dose after going to bed)
What Sets This Drug Apart
- Ultra-short acting with t1/2 ~1 hour — unique among hypnotics for minimal next-day residual effects despite rapid onset
- Selective omega-1 GABA-A agonist (NOT benzodiazepine) with preferential binding to alpha-1 subunit — distinct mechanism from BZDs
- Can be taken immediately before bed OR after going to bed with sleep difficulty due to rapid onset — more flexible timing than other hypnotics
- No active metabolites; all metabolites pharmacologically inactive — eliminates accumulation concerns
- Boxed warning for complex sleep behaviors including sleep-driving; can cause serious injuries/death at any dose or with 5 mg in drug-naive users
- Approval only for sleep-onset insomnia, NOT sleep maintenance or total sleep time; dose-dependent rebound insomnia may occur
Boxed Warning
Complex sleep behaviors: sleep-walking, sleep-driving, other complex behaviors may occur
Boxed Warning
DEA Schedule IV: abuse/dependence potential